Technical Analysis for TGTX - TG Therapeutics, Inc.

Grade Last Price % Change Price Change
D 44.65 1.71% 0.75
TGTX closed up 1.71 percent on Tuesday, April 13, 2021, on 47 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical TGTX trend table...

Date Alert Name Type % Chg
Outside Day Range Expansion 0.00%
MACD Bearish Centerline Cross Bearish -0.31%
50 DMA Resistance Bearish -4.39%
Narrow Range Bar Range Contraction -4.39%
NR7 Range Contraction -4.39%
NR7-2 Range Contraction -4.39%
50 DMA Resistance Bearish -3.21%
MACD Bearish Signal Line Cross Bearish -3.21%
Narrow Range Bar Range Contraction -3.21%
NR7 Range Contraction -3.21%
Older End-of-Day Signals for TGTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Trending on StockTwits about 4 hours ago
Fell Below Previous Day's Low about 9 hours ago
Lower Bollinger Band Support about 9 hours ago
Down 1% about 9 hours ago
60 Minute Opening Range Breakdown about 10 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

TG Therapeutics, Inc. Description

TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Treatment Of Cancer Pharmaceutical Products Monoclonal Antibody Monoclonal Antibodies Lymphoma Antibody Drug Conjugates Hematological Malignancies Camidanlumab Tesirine Cd20 Lymphocytes

Is TGTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 56.74
52 Week Low 9.94
Average Volume 1,330,958
200-Day Moving Average 34.96
50-Day Moving Average 46.79
20-Day Moving Average 46.67
10-Day Moving Average 46.32
Average True Range 2.48
ADX 13.66
+DI 16.60
-DI 26.48
Chandelier Exit (Long, 3 ATRs ) 43.80
Chandelier Exit (Short, 3 ATRs ) 49.75
Upper Bollinger Band 50.29
Lower Bollinger Band 43.05
Percent B (%b) 0.22
BandWidth 15.51
MACD Line -0.43
MACD Signal Line -0.13
MACD Histogram -0.2967
Fundamentals Value
Market Cap 5.65 Billion
Num Shares 127 Million
EPS -1.96
Price-to-Earnings (P/E) Ratio -22.79
Price-to-Sales 20013.68
Price-to-Book 21.66
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 47.30
Resistance 3 (R3) 47.12 46.05 46.86
Resistance 2 (R2) 46.05 45.37 46.14 46.71
Resistance 1 (R1) 45.35 44.96 45.70 45.53 46.57
Pivot Point 44.28 44.28 44.46 44.37 44.28
Support 1 (S1) 43.58 43.60 43.93 43.77 42.73
Support 2 (S2) 42.51 43.19 42.60 42.59
Support 3 (S3) 41.81 42.51 42.44
Support 4 (S4) 42.00